EUCTR2016-002858-20-ES
Active, not recruiting
Phase 1
A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial). - DUNE Trial
GETNE (Grupo Español de Tumores Neuroendocrinos)0 sitesDecember 9, 2016
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin.
- Sponsor
- GETNE (Grupo Español de Tumores Neuroendocrinos)
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Written informed consent obtained prior to any protocol\-related procedures.
- •2\.Age \>18 years at time of study entry.
- •3\.Subjects must have histologically confirmed diagnosis of one of the following advanced/metastatic neuroendocrine tumor types:
- •a)Cohort 1: Well\-moderately differentiated neuroendocrine tumors of the lung (mitotic count \=10 mitoses/10HPF), also known as typical and atypical lung carcinoids, that have progressed to prior somatostatin analog therapy and/or one prior targeted therapy or chemotherapy (only one prior systemic therapy, with the exception of patients that have been treated with somatostatin analogues and other systemic treatment, when two prior treatments are allowed).
- •b)Cohort 2: Well\-moderately differentiated G1/G2 (WHO grade 1 and 2\)Gastrointestinal neuroendocrine tumors after progression to somatostatin analogs and one targeted therapy (prior targeted therapy could be everolimus or a multikinase inhibitor). Prior therapies with interferon alpha\-2b or radionucleotide therapy are allowed.
- •c)Cohort 3: Well\-moderately differentiated neuroendocrine tumors G1/G2 (WHO grade 1 and 2\) from pancreatic origin after progression to standard therapies (chemotherapy, somatostatin analogs and target therapy); patients must be treated with at least two prior systemic treatment lines and a maximum of four previous treatment lines.
- •d)Cohort 4: Neuroendocrine neoplasms (WHO grade 3\) of gastroenteropancreatic origin of unknown primary site (excluding lung primary tumors) after progression to first\-line chemotherapy with a platinum based regimen.
- •4\.For patients included in cohorts 1, 2 and 3: WHO Classification G1/G2 (mitotic count \=10 mitoses x 10 HPF) lung typical and atypical carcinoids for cohort 1, G1/G2 (Ki67\=20% and mitotic count \=20 mitoses/10 HPF) gastrointestinal for cohort 2 (including stomach, small intestine and colorectal origins), G1/G2 (Ki67\=20% and mitotic count \=20 mitoses/10 HPF) pancreatic for cohort 3\.
- •5\.For patients included in cohort 4: WHO classification G3 (Ki67\>20% or mitotic count \>20 mitoses/10 HPF) gastroenteropancreatic neuroendocrine carcinomas (NEC) or liver metastases of G3 NEC of unknown primary site.
- •6\.Subjects must have evidence of measurable disease meeting the following criteria:
Exclusion Criteria
- •1\.Involvement in the planning and/or conduct of the study. 2\.Participation in another clinical study with an investigational product within 4 weeks (w).
- •3\.WHO Classification G3 neuroendocrine neoplasms of lung origin (oat cell/large cell lung cancer). 4\.Prior treatment with anti\-PDL\-1/anti\-PD\-1 or anti\-CTL\-4 therapy. 5\.Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses, known/evidence of acute or chronic hepatitis B, hepatitis C, known history of Human Immunodeficiency Virus, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the giving of written informed consent. 6\.Known/previous diagnosis of tuberculosis.
- •7\.Current/previous immunosuppressive medication within 28 days (d) before first dose of durvalumab or tremelimumab, except for intranasal/inhaled corticosteroids or systemic corticosteroids at physiological doses(\<10mg/d of prednisone, or an equivalent corticosteroid).
- •8\.Active/prior documented autoimmune disease within the past 2 y (vitiligo, Grave’s disease, or psoriasis not requiring systemic treatment within the past 2 y are not excluded).
- •9\.Active/prior documented inflammatory bowel disease (Crohn’s disease, ulcerative colitis).
- •10\.History of allogeneic organ transplant.
- •11\.History of hypersensitivity to durvalumab, tremelimumab or any excipient.
- •12\.Immunodeficiency or are receiving systemic steroids or any other immunosuppressive within 28d prior to the IMP's first dose.
- •13\.Knowledge of active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate only if these are stable \[with no evidence of progression confirmed by magnetic resonance imaging, for \=4w prior to the first IMP dose IMP and any neurologic symptoms must have returned to baseline], no evidence of new/enlarging brain metastases, and not used steroids for brain metastases for at least 7d prior to IMP. Subjects with carcinomatous meningitis are excluded regardless of clinical stability.
- •14\.Receipt of live attenuated vaccination within 30d prior to study entry or within 30d of receiving the IMP. (Only killed virus vaccines used for seasonal influenza vaccines for injection are allowed).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Durvalumab plus tremelimumab for progressive, refractory advanced thyroid carcinomaAdvanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary,follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC).Advanced medullary thyroid carcinoma (MTC)Advanced anaplastic thyroid cancer (ATC)MedDRA version: 20.0Level: PTClassification code 10076603Term: Poorly differentiated thyroid carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10002240Term: Anaplastic thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10016935Term: Follicular thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10071027Term: Thyroid cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10071028Term: Thyroid cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001066-42-ESSpanish Group of Neuroendocrine Tumors (GETNE)84
Completed
Phase 2
on small cell lung cancer trial of durvalumab and tremelimumab in advanced epidermal growth factor receptor (EGFR) mutant disease.EGFR mutant advanced non small cell lung cancer.Cancer - Lung - Non small cellACTRN12618001742268niversity of Sydney100
Not yet recruiting
Phase 2
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)2024-515240-24-00Grupo Espanol Multidisciplinar En Cancer Digestivo60
Completed
Phase 2
Phase II study of Durvalumab (MEDI4736) Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients(Dolphin study: WJOG11619L)non-small-cell lung cancerJPRN-jRCT2080224763Motoko Tachihara (Coordinating Investigator)35
Active, not recruiting
Phase 1
A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-003998-17-BEGrand Hôpital de Charleroi57